AiCuris’ Licensing Partner MSD Demonstrates Efficacy in Phase 3 Study with PREVYMIS® for Prevention of Cytomegalovirus Disease in Adults After Kidney Transplantation Written by Kai Schmitz on 24th October 2022. Posted in Client News. Previous Next